The trial, registered as NCT05782426, was a single-arm study conducted at Jiangsu Cancer Hospital and its collaborators, enrolling adults with untreated stage IIIB to IV non-squamous non-small cell lung cancer. All participants received the three-drug combination intravenously every three weeks for four to six cycles, followed by a maintenance phase in which they continued sintilimab alone or together with a reduced dose of the micellar paclitaxel for up to two years, or until the disease progressed, toxicity became unacceptable, or another anti-cancer therapy was started. The design included a safety run-in stage before the formal efficacy evaluation, a common safeguard in early-phase oncology studies intended to confirm that an aggressive dosing strategy can be delivered without excessive harm before the cohort is expanded.

The technical heart of the study lies in the first component of the regimen. Paclitaxel, one of the most widely used cytotoxic agents in oncology, works by stabilizing microtubules and preventing cancer cells from completing cell division. But the drug is notoriously insoluble in water, and conventional formulations rely on solvents such as Cremophor that trigger hypersensitivity reactions and require premedication. Nanoparticle albumin-bound paclitaxel was developed to sidestep those solvent toxicities, and polymeric micellar paclitaxel, the formulation tested here, goes a step further. The drug is packaged inside nanoscale polymer micelles, self-assembling structures with a hydrophobic core that sequesters paclitaxel and a hydrophilic shell that stabilizes the particle in the bloodstream. According to the researchers, this optimized formulation improves the drug’s pharmacokinetics and enhances tumor-targeted delivery, exploiting the leaky vasculature of tumors, a phenomenon known as the enhanced permeability and retention effect, to concentrate cytotoxic payload inside malignant tissue while limiting exposure to healthy organs.

Why does that matter for immunotherapy? The third component of the regimen, sintilimab, is a programmed cell death protein 1 inhibitor, an immune checkpoint blockade antibody developed by Innovent Biologics that releases the molecular brakes on T cells, allowing them to recognize and attack tumor cells. Cytotoxic chemotherapy and checkpoint inhibitors are not simply additive; chemotherapy can itself make tumors more visible to the immune system. Paclitaxel has been associated with immunogenic cell death, a mode of tumor killing that releases tumor antigens and danger signals, promoting dendritic cell activation and T cell priming. A micellar formulation that delivers more paclitaxel to the tumor could, in principle, amplify this immunogenic effect, turning the chemotherapy into a personalized in situ vaccine that primes the immune system for the checkpoint inhibitor to sustain the attack.

The dosing strategy in the trial was deliberately ambitious. Patients received 230 milligrams per square meter of body surface area of pm-Pac in the first cycle, together with carboplatin at an area-under-the-curve dose of 5 milligrams per milliliter per minute and a fixed 200-milligram dose of sintilimab. From the second cycle onward, the pm-Pac dose could be escalated to 300 milligrams per square meter, a level that would be difficult to tolerate with solvent-based formulations, provided patients maintained a minimum neutrophil count of at least 1.0 times 10 to the ninth per liter, platelets of at least 80 times 10 to the ninth per liter, and had experienced no grade 2 to 4 non-hematologic toxicity. This escalation logic reflects a core principle of chemo-immunotherapy: if the chemotherapy is meant to fuel the immune response, delivering a sufficiently potent dose matters, but only when the patient’s bone marrow and organs can withstand it.

The efficacy results were the headline finding. Among 28 treated patients, with a median follow-up of 25.0 months as of the January 28, 2026 data cutoff, the objective response rate reached 78.6 percent, meaning nearly four in five patients experienced a measurable shrinkage of their tumors. The disease control rate, which also counts patients whose tumors remained stable, was 89.3 percent. Responses proved durable: the median duration of response was 24.2 months, and median progression-free survival was 18.2 months, with an estimated 61.3 percent of patients still free of progression at 12 months and 43.8 percent at 24 months. Notably, 11 patients, or 39.3 percent of the cohort, completed the full protocol-specified two years of maintenance treatment with sintilimab plus pm-Pac. Overall survival data remained immature at the time of analysis, so the ultimate impact of the regimen on how long patients live has not yet been established.

Importantly, the benefit appeared to extend across levels of programmed death ligand-1 expression, the biomarker clinicians currently use to predict who will respond to checkpoint inhibitors. The authors report that the combination showed promising efficacy in EGFR and ALK-negative advanced or metastatic non-squamous non-small cell lung cancer regardless of PD-L1 status. That is a meaningful point, because patients whose tumors express little or no PD-L1 historically derive less benefit from immunotherapy-containing regimens, and a strategy that does not depend on this biomarker could widen access to effective first-line treatment for a broader population.

Safety, however, was not trivial. Grade 3 or worse treatment-emergent adverse events occurred in 75.0 percent of patients, a substantial burden that reflects the intensified chemotherapy dosing. Adverse events led to treatment interruption in four patients and permanent discontinuation of study therapy in seven. Immune-related adverse events of grade 3 or higher affected 32.1 percent of patients, and the trial recorded one death from grade 5 immune-related pneumonitis, a severe inflammation of lung tissue triggered by the unleashed immune system. The authors characterize the safety profile as manageable, and the escalation rules and maintenance dose cap of 230 milligrams per square meter were designed to keep toxicity in check, but the figures underscore that this is an intensive regimen requiring careful monitoring, experienced supportive care, and prompt management of immune-related complications.

The study’s limitations are inherent to its design. With 28 patients and no control arm, the results cannot establish that the micellar formulation outperforms standard paclitaxel or albumin-bound paclitaxel in combination with platinum and immunotherapy; single-arm trials generate signals, not proof. Selection of generally fit patients, potential publication bias toward positive results, and the small sample size all warrant caution. The authors themselves conclude that the findings support further evaluation in randomized controlled trials, which would be needed to determine whether the higher dose intensity and altered pharmacokinetics of pm-Pac translate into genuine survival advantages over existing standards of care.

Even so, the trial adds to a growing body of evidence that nanotechnology-enabled drug delivery can reshape cancer treatment in concrete clinical terms. By re-engineering a familiar molecule at the nanoscale, the researchers achieved a dosing ceiling that older formulations could not safely reach, and paired it with immunotherapy in a way that may harness chemotherapy’s immune-priming effects. For a disease that kills more people globally than any other cancer, a regimen producing responses in nearly 80 percent of patients and keeping more than 40 percent progression-free at two years is a result that will draw attention from oncologists everywhere. Whether pm-Pac, carboplatin, and sintilimab will earn a place in routine first-line care now depends on the larger randomized trials that this phase II study was designed to justify, and on whether its efficacy can be reproduced while taming the considerable toxicity that came with it.

Subject of Research: First-line chemo-immunotherapy with nanoparticle polymeric micellar paclitaxel and sintilimab for advanced non-squamous non-small cell lung cancer

Article Title: Nanoparticle polymeric micellar paclitaxel (pm-Pac), platinum, and sintilimab as first-line treatment for advanced or metastatic non-squamous non-small cell lung cancer: a phase II study

Article References: Wang, X., Wang, L., Yu, S., Liao, D., Liu, C., Li, L., Peng, W., Wang, X., Zhang, X., Guo, Z., Li, X., Li, X., Yu, X., Zhou, Y., Tang, Y., & Shi, M. (2026). Nanoparticle polymeric micellar paclitaxel (pm-Pac), platinum, and sintilimab as first-line treatment for advanced or metastatic non-squamous non-small cell lung cancer: a phase II study. BMC Medicine. https://doi.org/10.1186/s12916-026-05281-1

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05281-1

Keywords: non-small cell lung cancer, polymeric micellar paclitaxel, sintilimab, immunotherapy, nanoparticle drug delivery, phase II trial, carboplatin, PD-L1, progression-free survival, chemo-immunotherapy, oncology, BMC Medicine